Pharmaceutical

Bio-Thera signs US deal with Intas for golimumab biosimilar

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in the US.

Feb 11, 2025 - 06:00
Bio-Thera signs US deal with Intas for golimumab biosimilar
Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in the US.
Read the original article

Tags:

Previous Article

Obesity market to reach $173.5 billion by 2031

Next Article

Boehringer seeks approval of lung disease drug after second Phase III success

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Iovance looks to advance its non-small cell lung cancer therapy

Iovance looks to advance its non-small cell lung cancer...

Jul 11, 2023

STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more

STAT+: Pharmalittle: We’re reading about a nixed Medica...

Mar 4, 2024

STAT+: Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

STAT+: Solicitor general urges Supreme Court to review ...

Mar 30, 2023